SCHEMBL6701038

SCHEMBL6701038

CC(C)(N)CNc1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.38
PIM1 P11309 1/20 0.38
FLT3 P36888 1/20 0.38
CDK7 P50613 1/20 0.38
KCNH2 Q12809 1/20 0.38
PIM3 Q86V86 1/20 0.38
HASPIN Q8TF76 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
ALDH1A1 P00352 7/20 0.38
MAPT P10636 5/20 0.38
HTT P42858 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MAPK1 P28482 2/20 0.38
XBP1 P17861 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12932913 0.83 ALDH1A1 (0.40) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL6698866 0.81 MAPT (0.54) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL13846824 0.80 MEN1 (0.40) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL10852321 0.79 SLC6A2 (0.50) ALDH1A1MEN1KMT2ANPC1RAB9A
SCHEMBL14397073 0.79 CA1 (0.46) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL8613449 0.79 KMT2A (0.42) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL6702352 0.78 TAAR1 (0.46) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL7945715 0.76 ALDH1A1 (0.50) ALDH1A1MAPTHTTMEN1KMT2A
SCHEMBL6698887 0.76 GAA (0.59) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL6702634 0.76 MEN1 (0.47) ALDH1A1MAPTHTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968580-B2 Imidazolidin-2-one derivatives as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2011-06-28 US disclosed
US-20090215848-A1 Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS) LANTER JAMES C 2009-08-27 US disclosed
US-20040180925-A1 Dipeptidylpeptidase-IV inhibitor KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-16 US disclosed
EP-1354882-A1 DIPEPTIDYL PEPTIDASE IV INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215848-A1 Novel imidazolidIn-2-one derivatives as selective androgen receptor modulators (SARMS) AR, NR5A1, NR5A2 KIT 921/4885PIM1 1428/4885FLT3 2200/4885
US-20040180925-A1 Dipeptidylpeptidase-IV inhibitor DPP4, DPP3, DPP9 KIT 2168/4885PIM1 2790/4885FLT3 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.